Sign In
Buy IBIO
$1.84
+0.0800 (+4.55%)
At Close: Jun 03, 2026
Avoid iBio Stock In the Near-Term As Competitors Keep Racing Ahead
05:00pm, Wednesday, 16'th Sep 2020
At the moment, it’s better to just avoid iBio stock. There are far better opportunities to be found in this market.
9 Reasons Why The Race For Major COVID-19 Vaccine Revenues Has Greatly Narrowed
10:06am, Wednesday, 02'nd Sep 2020
The huge amount of Operation Warp Speed funding for its six vaccines has helped them become somewhat dominant leaders in the race for a sizable share of the market.
Vaccine Race Also-ran iBio Stock Won't See Earlier Highs Anytime Soon
09:01am, Friday, 28'th Aug 2020
Both the potential rewards and risks offered by IBIO stock are high. But for Covid-19 vaccine bets, there are better options for investors.
iBio: A Compelling Short
08:30am, Tuesday, 25'th Aug 2020
iBio has broken below a key technical level. The company is behind over 20 other names in COVID-19 vaccine development.
GlaxoSmithKline: Attention Is Now Shifting To Vaccine Manufacturing
09:39am, Friday, 21'st Aug 2020
Current state of COVID-19 vaccine production indicates that GSK is both in vaccine development and manufacturing.
Is iBio's (NYSEMKT:IBIO) 216% Share Price Increase Well Justified?
04:52pm, Wednesday, 19'th Aug 2020
iBio, Inc. (NYSEMKT:IBIO) shareholders might be rather concerned because the share price has dropped 60% in the last...
Xerox and Inozyme See Activist Action
08:55pm, Friday, 14'th Aug 2020
Icahn Capital lifted its position in printing and imaging firm Xerox to 25,269,522 shares. Longitude Capital initiated a position of 2,819,379 shares in Inozyme, a newly public biopharmaceutical firm.
It's Now Time for iBio to Deliver the Goods
11:55am, Tuesday, 11'th Aug 2020
If not, IBIO stock could end up stumbling on a narrowing window of opportunity.
iBio Is One of the Top Pandemic Opportunities
06:58pm, Monday, 10'th Aug 2020
With iBio's FastPharming technology and its vaccines in the works, IBIO stock is well worth gambling on at its current prices.
iBio Provides Update on IBIO-201 COVID-19 Vaccine Program
11:15am, Monday, 10'th Aug 2020
\- IBIO-201 Demonstrates Ability to Elicit anti-SARS-CoV-2 Immune Response in Preclinical Studies -NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Com
iBio Stock Is a Highly Speculative Covid-19 Play That Isn't Worth It
12:47pm, Wednesday, 05'th Aug 2020
Too much speculation and too-weak fundamentals make IBIO stock a sell today for risk-averse, disciplined investors.
There's a Better Way to Bet on iBio Stock if You Prefer Stability
12:03pm, Tuesday, 04'th Aug 2020
With the GERM ETF, you have a more well-rounded exposure to biotechnology and pharmaceuticals without the long shot proposition of IBIO stock.
7 Penny Stocks for the Valiant Investor
01:58pm, Friday, 31'st Jul 2020
These seven penny stocks have the potential to offer short-term returns if things go according to plan for the firms over the next few weeks.
IBio's stock soars, but Novavax and Inovio stocks fall amid news on other COVID-19 vaccine candidates
02:17pm, Monday, 20'th Jul 2020
Shares of companies with COVID-19 vaccine candidates were mixed in volatile trading Monday, after the promising results from trials of vaccine candidates...
IBio's stock soars, but Novavax and Inovio stocks fall amid news on other COVID-19 vaccine candidates
02:17pm, Monday, 20'th Jul 2020
Shares of companies with COVID-19 vaccine candidates were mixed in volatile trading Monday, after the promising results from trials of vaccine candidates from Pfizer Inc. and BioNTech SE and AstraZe
